Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Hepatocellular 202Carcinoma, Renal Cell 68Liver Neoplasms 61Neoplasms 53Neoplasm Metastasis 34Leukemia, Myeloid, Acute 34Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 29Melanoma 24Kidney Neoplasms 21Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Recurrence 13Glioblastoma 13Thyroid Neoplasms 11Colorectal Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Carcinoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

Cisplatin 16Cetuximab 16Radiotherapy, Intensity-Modulated 10Radiotherapy 7Docetaxel 7Fluorouracil 5Erlotinib Hydrochloride 5Everolimus 4Carboplatin 4Sorafenib 3Paclitaxel 3Fluorodeoxyglucose F18 3Chemotherapy, Adjuvant 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3Ultrasonography 2Taxes 2Sirolimus 2Radiotherapy, Conformal 2Radiation 2Platinum 2Photochemotherapy 2Magnetic Resonance Spectroscopy 2Cryosurgery 2Celecoxib 2Biopsy 2Bevacizumab 21-phenyl-3,3-dimethyltriazene 21,2-diaminocyclohexaneplatinum II citrate 2temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Tongue Neoplasms × Sorafenib × Clear all
NCT00939627 2026-03-10

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

National Cancer Institute (NCI)

Phase 2 Completed
55 enrolled 10 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT02035527 2018-05-24

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
3 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00096512 2013-02-28

S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡